Hutchison China MediTech Limited Net Income | HCM

Net profit is a financial indicator that reflects the remaining amount of money after deducting all expenses and taxes from the company’s total income over a certain period of time. It is one of the key indicators of a company’s financial stability and success.

Net profit is the portion of total profit remaining after taxes and depreciation have been deducted.^[1]

It is the result of a company’s operations and reflects its efficiency in managing resources, controlling expenses, and generating income. It includes all operating revenues and expenses, such as sales of goods or services, production costs, administrative expenses, taxes, and other financial metrics.

The calculation of net profit includes the deduction of all necessary expenses such as employee salaries, rent, utilities, taxes, and other mandatory payments. After all these expenses are deducted from the total income, the remaining amount is considered the company’s net profit.

Net profit is an important indicator of a company’s financial health, as it reflects its ability to generate earnings and manage its finances. High net profit indicates business success, competitiveness, and efficiency in resource utilization. It also allows a company to invest in its development, pay dividends to shareholders, or create reserve funds for unforeseen situations.

It serves as a basis for calculating other financial indicators, such as return on sales, return on assets, or return on equity. It is also used to assess the performance of management and make decisions regarding the future development of the company.

However, it should be noted that net profit can be affected by various factors, such as economic conditions, changes in legislation, market competition, and other external influences. Therefore, companies must be prepared for possible changes and take measures to ensure the stability of their financial results.

Annual Net Income Hutchison China MediTech Limited

2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
457 M	37.7 M	101 M	-361 M	-195 M	-126 M	-106 M	-74.8 M	-26.7 M	-43 M	7.99 M	5.37 M	5.92 M	3.64 M	710 K

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
457 M	-361 M	-20.9 M

Quarterly Net Income Hutchison China MediTech Limited

2025-Q4	2025-Q2	2024-Q4	2024-Q2	2023-Q4	2023-Q2	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
457 M	455 M	37.7 M	25.8 M	101 M	169 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-19.9 M	-	-	-	-11.7 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
457 M	-19.9 M	152 M

References

Bhamornsiri, S., & Wiggins, C. (2001). Comprehensive income disclosures. The CPA Journal, 71(10), 54.

Net Income of other stocks in the Biotechnology industry

Issuer	Net Income	Price	% 24h	Market Cap	Country
AbbVie ABBV	1.82 B	$ 263.04	0.49 %	$ 465 B	USA
AbCellera Biologics ABCL	-146 M	$ 11.41	2.15 %	$ 3.41 B	Canada
Фармсинтез LIFE	-525 M	-	-	-	Russia
Aclaris Therapeutics ACRS	-64.9 M	$ 5.53	6.02 %	$ 678 M	USA
ADC Therapeutics SA ADCT	-143 M	$ 1.09	3.74 %	$ 139 M	Schweiz
Amryt Pharma plc AMYT	1 M	-	-	$ 621 M	Britain
Evelo Biosciences EVLO	-115 M	-	-14.46 %	$ 27.9 M	USA
Allakos ALLK	-116 M	-	-	$ 28.6 M	USA
Checkmate Pharmaceuticals CMPI	-61.4 M	-	-	$ 231 M	USA
Clovis Oncology CLVS	-64.4 M	-	-7.23 %	$ 13 M	USA
Chimerix CMRX	-88.4 M	-	-	$ 756 M	USA
Concert Pharmaceuticals CNCE	-80.1 M	-	-	$ 401 M	USA
ADMA Biologics ADMA	147 M	$ 8.61	0.16 %	$ 2.05 B	USA
Eiger BioPharmaceuticals EIGR	-75 M	-	-9.21 %	$ 2.55 M	USA
89bio ETNB	-367 M	-	-	$ 1.55 B	USA
Freeline Therapeutics Holdings plc FRLN	-89 M	-	-	$ 384 M	Britain
Fusion Pharmaceuticals FUSN	-94.9 M	-	-	$ 1.41 B	Canada
Guardion Health Sciences GHSI	158 K	-	-0.31 %	$ 3.64 M	USA
Genocea Biosciences GNCA	-33.2 M	-	-15.0 %	$ 3.04 M	USA
Gritstone Oncology GRTS	-138 M	-	0.42 %	$ 213 M	USA
G1 Therapeutics GTHX	-48 M	-	-	$ 370 M	USA
Harpoon Therapeutics HARP	-67.7 M	-	-	$ 763 M	USA
Humanigen HGEN	-70.7 M	-	-81.12 %	$ 4.28 M	USA
HOOKIPA Pharma HOOK	-43.5 M	-	-6.92 %	$ 79.4 M	USA
Intercept Pharmaceuticals ICPT	-20.8 M	-	-	$ 643 M	USA
IGM Biosciences IGMS	-196 M	-	-	$ 76.9 M	USA
IMV IMV	-38 M	-	-	$ 13.1 M	Canada
Intra-Cellular Therapies ITCI	-16.9 M	-	-	$ 13.6 B	USA
Kinnate Biopharma KNTE	-113 M	-	-	$ 123 M	USA
Chinook Therapeutics KDNY	-188 M	-	-	$ 2.6 B	USA
Kaleido Biosciences KLDO	-90.3 M	-	-3.69 %	$ 12.4 M	USA
Kronos Bio KRON	-86.1 M	-	1.49 %	$ 50.8 M	USA
Karuna Therapeutics KRTX	-434 M	-	-	$ 12.2 B	USA
Landos Biopharma LABP	-21.9 M	-	0.58 %	$ 144 M	USA
La Jolla Pharmaceutical Company LJPC	19.7 M	-	-	$ 154 M	USA
LogicBio Therapeutics LOGC	-40 M	-	-	$ 229 M	USA
Lumos Pharma LUMO	-34 M	-	-	$ 35.3 M	USA
Merrimack Pharmaceuticals MACK	-1.18 M	-	-	$ 216 M	USA
Stealth BioTherapeutics Corp MITO	-52.5 M	-	-	$ 23.9 M	USA
Mirati Therapeutics MRTX	-741 M	-	-	$ 3.3 B	USA
NexImmune NEXI	-32.3 M	-	70.13 %	$ 4.12 M	USA
9 Meters Biopharma NMTR	-43.8 M	-	-42.97 %	$ 1.05 M	USA
InVivo Therapeutics Holdings Corp. NVIV	-10.5 M	-	-37.48 %	$ 476 K	USA
Nymox Pharmaceutical Corporation NYMX	-4.49 M	-	-19.68 %	$ 18.4 M	Canada
ObsEva SA OBSV	-58.4 M	-	-15.52 %	$ 10.5 M	Schweiz
Oncorus ONCR	-77.4 M	-	-8.54 %	$ 3.19 M	USA
OncoSec Medical Incorporated ONCS	-34.2 M	-	31.87 %	$ 1.61 M	USA
Oncternal Therapeutics ONCT	-39.5 M	-	-24.12 %	$ 1.56 M	USA
Opiant Pharmaceuticals OPNT	3.01 M	-	-	$ 109 M	USA
Orchard Therapeutics plc ORTX	-151 M	-	1.02 %	$ 90.8 M	Britain